drugset / Trial / NCT07085468

A Study of LY3549492 in Healthy Weight Adult Participants

NCT07085468

Phase 2 Terminated 1 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindBasic science

Summary

The main purpose of this study is to evaluate the safety and tolerability of LY3549492 in adult participants with a healthy body max index (BMI) of 22 to 25 kilograms per square meter (kg/m2). Participation in the study will last about 13 months.

Timeline

Start
2025-07-21
Primary completion
2025-08-14
Completion
2025-08-14

Drugs

EvaluationDrugModalityDoseRoute
Subject LY3549492 Unknown Oral

Indications

No indication recorded.